Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly.

Eli Lillys Zepbound has outperformed Novo Nordisks Wegovy in a recent clinical trial, with patients losing more weight on ...

Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss ...

People who took Zepbound lost 17 pounds more on average after 72 weeks of treatment than those who were given Novo Nordisk’s ...

The trial enrolled 751 adults with obesity or overweight conditions and at least one weight-related medical problem ...

President-elect Donald Trump and his incoming administration are unlikely to attempt a wholesale restructuring of U.S.

"Pair this off with the continued surge of inflows to equity ETFs and it creates a developing case of hot sentiment. Keep in ...

Drugmaker Eli Lilly is claiming victory in the battle of weight loss drugs, now one of the most competitive and lucrative ...

By Gnaneshwar Rajan and Maggie Fick (Reuters) -U.S.-based vaccine maker Novavax said on Wednesday it will sell its ...